Karolinska Development's portfolio company Aprea Therapeutics receives FDA clearance to initiate Phase 1 study of APR-548 ... Oct 08
Novel CAR-T Cell immunotherapy for lymphoma advances to phase II clinical trial ... Oct 06
Manufacturing agreement for Autologous T-Cell Receptor-Based Cell Therapy... Sep 24
... Sep 08
Strategic collaboration for studying investigational treatments for patients with a variety of cancer types... Sep 05
-Advertisements-